Payload Information
General Information of This Payload
| Payload ID | PAY0SIIAW |
|||||
|---|---|---|---|---|---|---|
| Name | P2025 |
|||||
| Target | Glucocorticoid receptor (NR3C1) | |||||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
DB-2304 [Phase 1/2]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key inclusion for Part A: healthy volunteers aged 18-55; BMI-compliant; normal medical history/physical exams/lab tests/ECG; commitment to effective contraception and protocol compliance.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06625671 | Phase Status | PHASE1 | ||
| Clinical Description |
A Randomized, Double-Blind, Placebo- and Positive-Controlled, Single Ascending Dose Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DB-2304 Injection in Healthy Adult Participants
|
||||
| Primary Endpoint |
Primary safety endpoints include TEAEs and SAEs (monitored up to 112 days for Part A/196 days for Part B post-treatment), ECG parameters (HR/PR/QT/QTcF intervals), and vital sign measurements (weight, heart rate, pulse, respiratory rate, body temperature) with baseline change analysis.
|
||||